A COMPREHENSIVE STUDY TO INVESTIGATE THE IMMUNE RESPONSE OF VACCINATION IN CHILDREN AND YOUNG PEOPLE DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE
DOI:
https://doi.org/10.53555/nnmhs.v9i7.1755Abstract
Objectives: The objective of this study was to evaluate the immune response to vaccination in children and young individuals diagnosed with inflammatory bowel disease (IBD). The vaccine response may be influenced by both the underlying disease and its treatment in patients with IBDs.
Methods: The review compares the immune response of IBD patients to healthy controls and explores differences between those receiving immunosuppressive therapy (IS) and non-immunosuppressive therapy (NIS). The review aims to assess immune response adequacy, adverse events, and IBD exacerbations.
Results: Patients with IBD exhibited diverse immune responses, with influenza B showing the lowest response rate. Immunosuppressive therapy (IS) did not significantly affect response rates compared to non-IS treatment. Lower vaccine responses were associated with IS therapy, steroid use, and certain medications. In general, there were no significant differences in immune response between IBD patients and healthy individuals, except for lower responses to influenza B and hepatitis B vaccines. Adverse events following vaccination were well tolerated, with similar rates in IBD patients and healthy controls. Vaccination had limited impact on disease activity, with only a few isolated cases of IBD exacerbation reported.
Conclusions: The immunogenicity of vaccinations in children and young individuals with inflammatory bowel disease (IBD) is comparable to that of healthy individuals, and there is no significant difference in immune response between patients with IBD receiving immunosuppressive (IS) therapy and those without it. However, more research is required to thoroughly investigate this topic, as there are limited well-designed studies available.
References
Esposito S, Antoniol G, Labate M, Passadore L, Alvisi P, Daccò V, Ghizzi C, Colombo C, Principi N. Vaccines in Children with Inflammatory Bowel Disease: Brief Review. Vaccines (Basel). 2021 May 11;9(5):487. doi:
3390/vaccines9050487. PMID: 34064576; PMCID: PMC8151471.
Dembiński Ł, Dziekiewicz M, Banaszkiewicz A. Immune response to vaccination in children and young people with inflammatory bowel disease: A systematic review and meta-analysis. Journal of Pediatric Gastroenterology & Nutrition. 2020;71(4):423–32. doi:10.1097/mpg.0000000000002810
Phatak UP, Rojas-Velasquez D, Porto A, et al. Immune response to primary hepatitis B vaccination series in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2016;63:S374.
DeBruyn JC, Hilsden R, Fonseca K, et al. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. Inflamm Bowel Dis 2012;18:25–33
Nguyen DL, Nguyen ET, Bechtold ML. Effect of immunosuppressive therapies for the treatment of inflammatory bowel disease on response to routine vaccinations: a meta-analysis. Dig Dis Sci 2015;60:2446–53.
García-Serrano C., Mirada G., Marsal J.R., Ortega M., Sol J., Solano R., Artigues E.M., Estany P. Compliance with the guidelines on recommended immunization schedule in patients with inflammatory bowel disease: Implications on public health policies. BMC Public Health. 2020;20:1–8. doi: 10.1186/s12889-020-08850-y.
Gisbert JP, Villagrasa JR, Rodriguez-Nogueiras A, et al. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol 2012;107:1460–6.
Park SH, Yang SK, Park SK, et al. Efficacy of hepatitis A vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease. Inflamm Bowel Dis 2014;20:69–74.
Radzikowski A, Banaszkiewicz A, Lazowska-Przeorek I, et al. Immunogenecity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2011;17:1117–24
Ogimi C, Tanaka R, Saitoh A, et al. Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr Infect Dis J 2011;30:208–11
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
